Under the agreement, CPC expects to manage and oversee the activities of the Eligibility Review Committee, which will be responsible to identify and confirm the eligibility of no-option and poor option patients for participation in the REVIVE CLI clinical trials.
CPC president William Hiatt said they share their commitment to advancing the REVIVE Phase 3 clinical program for ixmyelocel-T to regulatory approval and to help provide a promising therapy to CLI patients.
"Aastrom’s clinical development program is a critically important translational step in the development of cellular therapies to treat human disease, a key objective of the University of Colorado Stem Cell Center," Hiatt said.